# A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1903

> **NCT04762407** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 57 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HGP1910
- **DRUG:** HGP1909
- **DRUG:** HCP1903

## Key facts

- **NCT ID:** NCT04762407
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-20
- **Primary completion:** 2021-02-24
- **Final completion:** 2021-02-24
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2022-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04762407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04762407, "A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1903". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04762407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*